Edward Tenthoff
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
182
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Initiates: Overweight | $35 | $19.45 | +79.95% | 1 | Oct 21, 2024 | |
| STRO Sutro Biopharma | Reiterates: Overweight | $11 | $3.55 | +209.86% | 6 | Oct 11, 2024 | |
| KRON Kronos Bio | Reiterates: Overweight | $6 | $0.99 | +506.06% | 6 | Oct 8, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $62 | $19.49 | +218.11% | 10 | Oct 8, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Overweight | $53 | $28.74 | +84.41% | 5 | Sep 23, 2024 | |
| SKYE Skye Bioscience | Reiterates: Overweight | $20 | $5.56 | +259.71% | 3 | Sep 20, 2024 | |
| OPK OPKO Health | Reiterates: Overweight | $3 | $1.51 | +98.68% | 6 | Sep 17, 2024 | |
| MRNA Moderna | Maintains: Overweight | $157 → $115 | $54.63 | +110.51% | 11 | Sep 13, 2024 | |
| SYRS Syros Pharmaceuticals | Reiterates: Overweight | $13 → $5 | $2.27 | +120.75% | 6 | Aug 13, 2024 | |
| CUE Cue Biopharma | Maintains: Overweight | $8 → $3 | $1.52 | +97.37% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $11 | $8.48 | +29.72% | 3 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $8.90 | +79.78% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.91 | +779.70% | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $50.76 | +106.86% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $44.36 | +102.89% | 3 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $12 | $1.26 | +852.38% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $2.43 | +146.91% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 | $0.38 | +1,214.41% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 → $9 | $1.11 | +710.81% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.44 | +247.22% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $37 → $24 | $21.26 | +12.89% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $3.21 | +367.29% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $46.47 | +20.51% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $217 | $273.91 | -20.78% | 12 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.47 | +304.86% | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $26.90 | +104.46% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $2.23 | +1,290.13% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.52 | +478.03% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $1.33 | +351.13% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.82 | +995.02% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $20.83 | +111.23% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $22.71 | +62.92% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3,036 → $880 | $0.25 | +354,738.71% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $595.58 | -40.56% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.46 | +9,146.58% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $471.12 | -31.44% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $34.12 | +5.51% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $3.66 | +583.06% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.58 | +25,677.63% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $16.22 | +226.76% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $1.30 | +106,053.85% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $843.60 | - | 11 | Feb 13, 2017 |
Capricor Therapeutics
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $19.45
Upside: +79.95%
Sutro Biopharma
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.55
Upside: +209.86%
Kronos Bio
Oct 8, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.99
Upside: +506.06%
Arrowhead Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $62
Current: $19.49
Upside: +218.11%
Dyne Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $53
Current: $28.74
Upside: +84.41%
Skye Bioscience
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $5.56
Upside: +259.71%
OPKO Health
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.51
Upside: +98.68%
Moderna
Sep 13, 2024
Maintains: Overweight
Price Target: $157 → $115
Current: $54.63
Upside: +110.51%
Syros Pharmaceuticals
Aug 13, 2024
Reiterates: Overweight
Price Target: $13 → $5
Current: $2.27
Upside: +120.75%
Cue Biopharma
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $1.52
Upside: +97.37%
Jul 23, 2024
Upgrades: Overweight
Price Target: $4 → $11
Current: $8.48
Upside: +29.72%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $8.90
Upside: +79.78%
Jun 21, 2024
Reiterates: Overweight
Price Target: $8
Current: $0.91
Upside: +779.70%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $50.76
Upside: +106.86%
Jun 17, 2024
Reiterates: Overweight
Price Target: $90
Current: $44.36
Upside: +102.89%
Jun 17, 2024
Maintains: Overweight
Price Target: $9 → $12
Current: $1.26
Upside: +852.38%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $2.43
Upside: +146.91%
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $0.38
Upside: +1,214.41%
Apr 3, 2024
Reiterates: Overweight
Price Target: $10 → $9
Current: $1.11
Upside: +710.81%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.44
Upside: +247.22%
Feb 28, 2024
Downgrades: Neutral
Price Target: $37 → $24
Current: $21.26
Upside: +12.89%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $3.21
Upside: +367.29%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $46.47
Upside: +20.51%
Dec 14, 2023
Maintains: Overweight
Price Target: $210 → $217
Current: $273.91
Upside: -20.78%
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $2.47
Upside: +304.86%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $26.90
Upside: +104.46%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $2.23
Upside: +1,290.13%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.52
Upside: +478.03%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $1.33
Upside: +351.13%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.82
Upside: +995.02%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $20.83
Upside: +111.23%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $22.71
Upside: +62.92%
May 13, 2022
Maintains: Overweight
Price Target: $3,036 → $880
Current: $0.25
Upside: +354,738.71%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $595.58
Upside: -40.56%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.46
Upside: +9,146.58%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $471.12
Upside: -31.44%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $34.12
Upside: +5.51%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $3.66
Upside: +583.06%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.58
Upside: +25,677.63%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $16.22
Upside: +226.76%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $1.30
Upside: +106,053.85%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $843.60
Upside: -